Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: ADHD guidelines in the UK suggest that children and adults who respond to pharmacological treatment should continue for as long as remains clinically effective, subject to regular review. To what extent patients persist with treatment from childhood and adolescence into adulthood is not clear. This study aims to describe, in UK primary care, the persistence of pharmacological treatment for patients with ADHD who started treatment aged 6-17 years and to estimate the percentage of patients who continued treatment from childhood and adolescence into adulthood. METHODS: The Health Improvement Network (THIN) database was used to identify patients with ADHD who received their first prescription for methylphenidate/ dexamfetamine/atomoxetine, aged 6-17 years. Patients were monitored until their 'censored date' (the earliest of the following dates: date the last prescription coded in the database ended, end of the study period (31st December 2008), date at which they transferred out of their practice, date of death, the last date the practice contributed data to the database). Persistence of treatment into adulthood was estimated using Kaplan Meier analysis. RESULTS: 610 patients had follow-up data into adulthood. 213 patients (93.4% male) started treatment between 6-12 years; median treatment duration 5.9 years. 131 (61.5%) stopped before 18 years, 82 (38.5%) were still on treatment age ≥18 years. 397 patients (86.4% male) started treatment between 13-17 years; median treatment duration was 1.6 years. 227 (57.2%) stopped before 18 years, 170 (42.8%) were still on treatment age ≥18 years. The number of females in both age categories was too small to formally test for differences between genders in persistence of treatment. CONCLUSION: Persistence of treatment into adulthood is lower (~40%) compared with published rates of persistence of the condition (~65% when symptomatic definition of remission used). Due to the limited number of patients with data past 18 years, it is important that ongoing monitoring of prescribing into later adulthood is undertaken, particularly to observe the effects of recommendations in new guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FARAONE, S. V., BIEDERMAN, J., & MICK, E. (2006) · Psychological Medicine · doi:10.1017/s003329170500471x · Cited by 2,267
Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis
Simon, V., Czobor, P., Bálint, S., Mészáros, Á., & Bitter, I. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048827 · Cited by 1,601
Battle, D. E. (2013) · CoDAS · doi:10.1590/s2317-17822013000200017 · Cited by 1,569
Biederman, J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.816 · Cited by 1,498 · cited 1×
“fewer than five symptoms, or 36% of symptoms) or the maintenance of partial diagnostic status with impairment) resulted in a persistence rate of approximately 65% [14,15].”
Mental Health of Children and Young People in Great Britain, 2004: (557702010-001)
Green, H., McGinnity, A., Meltzer, H., Ford, T., & Goodman, R. (2005) · PsycEXTRA Dataset · doi:10.1037/e557702010-001 · Cited by 1,216
Kooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., et al. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-67 · Cited by 928 · cited 2×
“There is now consensus amongst experts that ADHD, diagnosed mainly using the broader Diagnostic and Statistical Manual of Mental Disorders 4th Edition (DSM-IV) criteria, may currently affect at least 1-2% of adults in the United Kingdom (UK) and 2-4% worldwide [2-6].”
Self-citationShaw, M., Hodgkins, P., Caci, H., Young, S., Kahle, J., Woods, A. G., & Arnold, L. E. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-99 · Cited by 759
Self-citationKessler, R. C., Adler, L. A., Barkley, R., Biederman, J., Conners, C. K., Faraone, S. V., Greenhill, L. L., Jaeger, S., Secnik, K., Spencer, T., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.001 · Cited by 663
Lewis, J. D., Schinnar, R., Bilker, W. B., Wang, X., & Strom, B. L. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1335 · Cited by 602
MTA Cooperative Group (2004) · Pediatrics · doi:10.1542/peds.113.4.754 · Cited by 589
Cited by
Matheson, L., Asherson, P., Wong, I. C. K., Hodgkins, P., Setyawan, J., Sasane, R., & Clifford, S. (2013) · BMC Health Services Research · doi:10.1186/1472-6963-13-184 · Cited by 126
Self-citationJordan, C. J., Harvey, R. C., Baskin, B. B., Dwoskin, L. P., & Kantak, K. M. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.04.020 · Cited by 38
Baskin, B. M., Dwoskin, L. P., & Kantak, K. M. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.01.019 · Cited by 20
“This is important because as many as 65% of adolescents with ADHD continue to meet criteria for the disorder in adulthood, and more than half stop taking ADHD medications by age 18 (McCarthy et al., 2012).”
BackgroundMurphy, D., Glaser, K., Hayward, H., Eklund, H., Cadman, T., Findon, J., Woodhouse, E., Ashwood, K., Beecham, J., Bolton, P., et al. (2018) · Programme Grants for Applied Research · doi:10.3310/pgfar06020 · Cited by 18
Self-citation
Metadata
- Authors
- McCarthy, S., Wilton, L., Murray, M. L., Hodgkins, P., Asherson, P., & Wong, I. C.
- Venue
- BMC Psychiatry
- Published
- 2012-12
- Volume
- 12
- Issue
- 1
- Pages
- 219-219
- ISSN
- 1471-244X (ISSN-L)
- OpenAlex
- W2155996137
- Cited by
- 42
- References
- 16
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence. https://app.cochat.ai/papers/10.1186/1471-244x-12-219
- The paper
- McCarthy, S., Wilton, L., Murray, M. L., Hodgkins, P., Asherson, P., & Wong, I. C. (2012). Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence. BMC Psychiatry. https://doi.org/10.1186/1471-244x-12-219
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.